Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, causing nearly 600 000 deaths each year. Increased risk of HCC due to chronic infection with hepatitis B virus (HBV) and exposure to dietary aflatoxins is responsible for many of these deaths. Prevention strategies targeting HBV infection and aflatoxin exposure could dramatically impact the rates of HCC. Universal HBV vaccination programs have begun in some high-risk areas. Strategies to reduce aflatoxin contamination in food stores have also been implemented. However, complete elimination of aflatoxin contamination might not be possible. For this reason, chemoprevention strategies which alter aflatoxin disposition are a practical strategy to reduce the incidence of HCC in populations with high dietary aflatoxin exposure. The mechanisms of aflatoxin-induced hepatocarcinogenesis are well known. This knowledge provides the basis for evaluation of both exposures to aflatoxin, as well as modulation of aflatoxin disposition by chemopreventive agents. Products of aflatoxin DNA damage and toxicity as well as other metabolites can be used as biomarkers to evaluate modulation of aflatoxin disposition. Modulation of aflatoxin disposition can be achieved through induction of conjugating and cytoprotective enzymes. Many of these enzymes are regulated through Kelch ECH-associating protein 1 (Keap1)–NF-E2-related factor 2(Nrf2)–antioxidant response element (ARE) signaling, making this pathway an important molecular target for chemoprevention. Rodent studies have identified several classes of chemopreventive agents which induce cytoprotective genes. These inducers include phenolic antioxidants, dithiolethiones, isothiocyanates, and triterpenoids. Furthermore, clinical interventions have shown that inducers of Keap1–Nrf2–ARE signaling increase cytoprotective enzyme expression, resulting in modulation of aflatoxin disposition. Much work remains to be done in order to take promising chemopreventive agents from preclinical evaluation to application in at-risk populations. However, appropriately designed clinical trials will aid in this process, which can have profound impact on the incidence of HCC.
Similar content being viewed by others
Article PDF
References
Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX, et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 2004; 127: S310–8.
Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204–9.
Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855–9.
Kensler TW, Qian GS, Chen JG, Groopman JD . Translational strategies for cancer prevention in liver. Nat Rev Cancer 2003; 3: 321–9.
Eaton DL, Gallagher EP . Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 1994; 34: 135–72.
Ishii K, Maeda K, Kamataki T, Kato R . Mutagenic activation of aflatoxin B1 by several forms of purified cytochrome P-450. Mutat Res 1986; 174: 85–8.
Bennett RA, Essigmann JM, Wogan GN . Excretion of an afla-toxin-guanine adduct in the urine of aflatoxin B1-treated rats. Cancer Res 1981; 41: 650–4.
Sabbioni G, Skipper PL, Buchi G, Tannenbaum SR . Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 1987; 8: 819–24.
Scholl PF, Musser SM, Groopman JD . Synthesis and characterization of aflatoxin B1 mercapturic acids and their identification in rat urine. Chem Res Toxicol 1997; 10: 1144–51.
Wild CP, Hudson GJ, Sabbioni G, Chapot B, Hall AJ, Wogan GN, et al. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in the Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1992; 1: 229–34.
Groopman JD, Zhu JQ, Donahue PR, Pikul A, Zhang LS, Chen JS, et al. Molecular dosimetry of urinary aflatoxins-DNA adducts in people living in Guangxi autonomous region, People's Republic of China. Cancer Res 1992; 52: 45–52.
Groopman JD, Wild CP, Hasler J, Junshi C, Wogan GN, Kensler TW . Molecular epidemiology of aflatoxin exposures: validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans. Environ Health Perspect 1993; 99: 107–13.
Groopman JD, Hall AJ, Whittle H, Hudson GJ, Wogan GN, Montesano R, et al. Molecular dosimetry of aflatoxin-N7-gua-nine in human urine obtained in the Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1992; 1: 221–7.
Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 2006; 66: 2488–94.
Kensler TW, Egner PA, Davidson NE, Roebuck BD, Pikul A, Groopman JD . Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res 1986; 46: 3924–31.
Groopman JD, Donahue PR, Zhu JQ, Chen JS, Wogan GN . Afla-toxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc Natl Acad Sci USA 1985; 82: 6492–6.
Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999; 91: 347–54.
Scholl P, Musser SM, Kensler TW, Groopman JD . Inhibition of aflatoxin Ml excretion in rat urine during dietary intervention with oltipraz. Carcinogenesis 1996; 17: 1385–8.
Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3–10.
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 3410–5.
McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI, et al. The Cap‘n’collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 2001; 61: 3299–307.
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313–22.
Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR, et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J 2002; 365: 405–16.
Chan K, Kan YW . Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA 1999; 96: 12 731–6.
Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S : Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002; 62: 5196–203.
Osburn WO, Wakabayashi N, Misra V, Nilles T, Biswal S, Trush MA, et al. Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of super-oxide anion. Arch Biochem Biophys 2006; 454: 7–15.
Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW . Modulation of gene expression by cancer chemo-preventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 2003; 278: 8135–45.
Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW : Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dithiole-3-thione. Mol Med 2001; 7: 135–45.
Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M . Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol 2001; 173: 154–60.
Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, et al. Role of phase 2 enzyme induction in chemo-protection by dithiolethiones. Mutat Res 2001; 480–481: 305–15.
Ramos-Gomez M, Dolan PM, Itoh K, Yamamoto M, Kensler TW . Interactive effects of nrf2 genotype and oltipraz on benzo [a]pyrene–DNA adducts and tumor yield in mice. Carcinogenesis 2003; 24: 461–7.
Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, et al. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res 2006; 66: 8293–6.
Telakowski-Hopkins CA, King RG, Pickett CB . Glutathione S-transferase Ya subunit gene: identification of regulatory elements required for basal level and inducible expression. Proc Natl Acad Sci USA 1988; 85: 1000–4.
Rushmore TH, Pickett CB . Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. J Biol Chem 1990; 265: 14648–53.
Moinova HR, Mulcahy RT . An electrophile responsive element (EpRE) regulates beta-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory subunit gene. Constitutive expression is mediated by an adjacent AP-1 site. J Biol Chem 1998; 273: 14683–9.
Li Y, Jaiswal AK . Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. J Biol Chem 1992; 267: 15097–104.
Favreau LV, Pickett CB . Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants. J Biol Chem 1991; 266: 4556–61.
Prestera T, Holtzclaw WD, Zhang Y, Talalay P . Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA 1993; 90: 2965–9.
Dinkova-Kostova AT, Holtzclaw WD, Kensler TW . The role of Keap1 in cellular protective responses. Chem Res Toxicol 2005; 18: 1779–91.
Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76–86.
Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24: 7130–9.
Furukawa M, Xiong Y . BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005; 25: 162–71.
Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA . The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004; 24: 8477–86.
McMahon M, Itoh K, Yamamoto M, Hayes JD . Keap1-depen-dent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003; 278: 21592–600.
Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 2002; 99: 11908–13.
Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 2006; 26: 221–9.
Yu R, Tan TH, Kong AT . Butylated hydroxyanisole and its metabolite tert-butylhydroquinone differentially regulate mito-gen-activated protein kinases. The role of oxidative stress in the activation of mitogen-activated protein kinases by phenolic antioxidants. J Biol Chem 1997; 272: 28962–70.
Yu R, Lei W, Mandlekar S, Weber MJ, Der CJ, Wu J, et al. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem 1999; 274: 27545–52.
Yu R, Chen C, Mo YY, Hebbar V, Owuor ED, Tan TH, et al. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J Biol Chem 2000; 275: 39907–13.
Huang HC, Nguyen T, Pickett CB . Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 2002; 277: 42769–74.
Lee JM, Hanson JM, Chu WA, Johnson JA . Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem 2001; 276: 20 011–6.
Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA . Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 2003; 23: 7198–209.
Kensler TW, Egner PA, Trush MA, Bueding E, Groopman JD . Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 1985; 6: 759–63.
Wattenberg LW, Lam LT . Inhibition of chemical carcinogenesis by phenols, coumarins, aromatic isothiocyanates, flavones, and indoles. In: Zedeck MS, Lipkin M, editors. Inhibition of tumor induction and development. New York: Plenum Press; 1981. p 1–22.
Cabral JR, Neal GE . The inhibitory effects of ethoxyquin on the carcinogenic action of aflatoxin B1 in rats. Cancer Lett 1983; 19: 125–32.
Nair S, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, et al. Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Pharm Res 2006; 23: 2621–37.
Hayes JD, Chanas SA, Henderson CJ, McMahon M, Sun C, Moffat GJ, et al. The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem Soc Trans 2000; 28: 33–41.
Ansher SS, Dolan P, Bueding E . Biochemical effects of dithiolthiones. Food Chem Toxicol 1986; 24: 405–15.
Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD . Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 1987; 47: 4271–7.
Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW . Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res 1991; 51: 5501–6.
Dimitrov NV, Bennett JL, McMillan J, Perloff M, Leece CM, Malone W . Clinical pharmacology studies of oltipraz—a potential chemopreventive agent. Invest New Drugs 1992; 10: 289–98.
Roebuck BD, Curphey TJ, Li Y, Baumgartner KJ, Bodreddigari S, Yan J, et al. Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz. Carcinogenesis 2003; 24: 1919–28.
Pietsch EC, Chan JY, Torti FM, Torti SV . Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem 2003; 278: 2361–9.
Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004; 64: 6424–31.
Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, et al. Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett 2006; 243: 170–92.
Gerhauser C, You M, Liu J, Moriarty RM, Hawthorne M, Mehta RG, et al. Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Res 1997; 57: 272–8.
Dinkova-Kostova AT, Fahey JW, Talalay P . Chemical structures of inducers of nicotinamide quinone oxidoreductase 1 (NQO1). Methods Enzymol 2004; 382: 423–48.
Hong F, Freeman ML, Liebler DC . Identification of sensor cys-teines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol 2005; 18: 1917–26.
Zhang Y, Kensler T W, Cho CG, Posner GH, Talalay P . Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 1994; 91: 3147–50.
Singh GB, Singh S, Bani S, Gupta BD, Banerjee SK . Anti-inflammatory activity of oleanolic acid in rats and mice. J Pharm Pharmacol 1992; 44: 456–8.
Nishino H, Nishino A, Takayasu J, Hasegawa T, Iwashima A, Hirabayashi K, et al. Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res 1988; 48: 5210–5.
Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003; 63: 5926–39.
Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, et al. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 2004; 64: 7927–35.
Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, Honda T, et al. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 2000; 11: 261–7.
Samudio I, Konopleva M, Hail N Jr, Shi YX, McQueen T, Hsu T, et al. 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 2005; 280: 36273–82.
Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003; 9: 2798–806.
Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG Jr, Suh N, et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem 2000; 43: 4233–46.
Honda T, Honda Y, Favaloro FG Jr, Gribble GW, Suh N, Place AE, et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 2002; 12: 1027–30.
Honda T, Gribble GW, Suh N, Finlay HJ, Rounds BV, Bore L, et al. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J Med Chem 2000; 43: 1866–77.
Talalay P, De Long MJ, Prochaska HJ . Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc Natl Acad Sci USA 1988; 85: 8261–5.
Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, Talalay P : Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci USA 2001; 98: 3404–9.
Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005; 102: 4584–9.
Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005; 65: 4789–98.
Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007; 6: 154–62.
Johnson DA, Andrews GK, Xu W, Johnson JA . Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J Neurochem 2002; 81: 1233–41.
Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl car-bamate in A/J mice. Cancer Res 2007; 67: 2414–9.
Sofowora GG, Choo EF, Mayo G, Shyr Y, Wilkinson GR . In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother Pharmacol 2001; 47: 505–10.
Gupta E, Olopade OI, Ratain MJ, Mick R, Baker TM, Berezin FK, et al. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin Cancer Res 1995; 1: 1133–8.
O'Dwyer PJ, Szarka CE, Yao KS, Halbherr TC, Pfeiffer GR, Green F, et al. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 1996; 98: 1210–7.
Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P . Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiol Biomarkers Prev 2001; 10: 501–8.
Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 2006; 55: 53–62.
Kensler TW, Chen JG, Egner PA, Fahey JW, Jacobson LP, Stephenson KK, et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxins–DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Bio-markers Prev 2005; 14: 2605–13.
Synthetic Triterpenoids for Treating Hematological Cancers, Solid Tumors, and Treatment-Related Toxicities [homepage on the Internet]. Dallas: Reata Pharmaceuticals, Inc; c2006. Available from: http://www.reatapharma.com/clinicalprograms.asp.
Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, et al. Compressing drug development timelines in oncology using phase ‘0’ trials. Nat Rev Cancer 2007; 7: 131–9.
Williams GM, Iatropoulos MJ . Inhibition of the hepatocarcinogenicity of aflatoxin B1 in rats by low levels of the phenolic antioxidants butylated hydroxyanisole and butylated hydroxytoluene. Cancer Lett 1996; 104: 49–53.
De Long MJ, Prochaska HJ, Talalay P . Induction of NAD(P)H: quinone reductase in murine hepatoma cells by phenolic anti-oxidants, azo dyes, and other chemoprotectors: a model system for the study of anticarcinogens. Proc Natl Acad Sci USA 1986; 83: 787–91.
Egner PA, Kensler TW, Prestera T, Talalay P, Libby AH, Joyner HH, et al. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis 1994; 15: 177–81.
Zhang Y, Talalay P, Cho CG, Posner GH . A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 1992; 89: 2399–403.
Fahey JW, Dinkova-Kostova AT, Stephenson KK, Talalay P . The “Prochaska” microtiter plate bioassay for inducers of NQO1. Methods Enzymol 2004; 382: 243–58.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by NIH grants (No CA39416, CA94076, and ES06052). Melinda Sue YATES was supported by T32 (No GM08763).
Rights and permissions
About this article
Cite this article
Yates, M., Kensler, T. Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol Sin 28, 1331–1342 (2007). https://doi.org/10.1111/j.1745-7254.2007.00688.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00688.x
Keywords
This article is cited by
-
Infiltration of M1, but not M2, macrophages is impaired after unilateral ureter obstruction in Nrf2-deficient mice
Scientific Reports (2017)
-
A serendipitous one-step conversion of 3H-1,2-dithiole-3-thione to (E)-3-[1-(alkylthio)alkylidene]-3H-1,2-dithiole: an experimental and theoretical study
Molecular Diversity (2014)
-
Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway
Nutrition & Metabolism (2013)
-
Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma
Investigational New Drugs (2011)
-
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation
Acta Pharmacologica Sinica (2010)